Products
Selegiline was commercially available in tablet form (Jumexal, generic). The drug was available in many countries from 1985 to 2016.
Structure and properties
Selegiline (C13H17N, Mr = 187.28 g/mol) is present in drugs as selegiline hydrochloride, a white crystalline powder that is readily soluble in water.
Effects
Selegiline (ATC N04BD01) has indirect dopaminergic and antidepressant properties. The effects are due to irreversible inhibition of the enzyme monoamine oxidase-B. This inhibits the breakdown of the neurotransmitter dopamine. In addition, selegiline inhibits the reuptake of dopamine into the presynapse. Unlike other MAO inhibitors, selegiline is selective and therefore no dietary restrictions are necessary.
Indications
- For the treatment of Parkinson’s disease.
- In the United States, selegiline is additionally approved as an antidepressant in the form of a transdermal patch. Other indications for use are under discussion.
Dosage
According to the professional information. The tablets are usually taken once or twice daily with or after meals.
Contraindications
- Hypersensitivity
- Extrapyramidal syndromes that are not due to dopamine deficiency
- Impaired renal or hepatic function
- Stomach or intestinal ulcers
- Pregnancy and lactation
- Selegiline must not be combined with certain medicines.
For complete precautions, see the drug label.
Interactions
Selegiline should not be combined with SSRIs, SNRIs, tricyclic antidepressants, sympathomimetics, pethidine, opioids, serotonin agonists, and bupropion. Concomitant administration may result in adverse effects.
Adverse effects
The most common possible adverse effects include dizziness, nausea, vomiting, dry mouth, movement disorders, psychosis, a drop in blood pressure, and a moderate increase in liver enzymes.